Financial Survey: SciClone Pharmaceuticals (SCLN) vs. CoLucid Pharmaceuticals (CLCD)

SciClone Pharmaceuticals (NASDAQ: SCLN) and CoLucid Pharmaceuticals (NASDAQ:CLCD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Earnings & Valuation

This table compares SciClone Pharmaceuticals and CoLucid Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SciClone Pharmaceuticals N/A N/A N/A $0.86 12.97
CoLucid Pharmaceuticals N/A N/A N/A ($3.43) -13.57

CoLucid Pharmaceuticals is trading at a lower price-to-earnings ratio than SciClone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


This table compares SciClone Pharmaceuticals and CoLucid Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SciClone Pharmaceuticals 27.39% 20.24% 18.42%
CoLucid Pharmaceuticals N/A -83.51% -70.62%

Institutional and Insider Ownership

72.8% of SciClone Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.2% of CoLucid Pharmaceuticals shares are owned by institutional investors. 5.2% of SciClone Pharmaceuticals shares are owned by insiders. Comparatively, 13.7% of CoLucid Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for SciClone Pharmaceuticals and CoLucid Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SciClone Pharmaceuticals 0 1 0 0 2.00
CoLucid Pharmaceuticals 0 0 0 0 N/A

SciClone Pharmaceuticals currently has a consensus price target of $14.00, suggesting a potential upside of 25.56%. Given SciClone Pharmaceuticals’ higher probable upside, analysts plainly believe SciClone Pharmaceuticals is more favorable than CoLucid Pharmaceuticals.


SciClone Pharmaceuticals beats CoLucid Pharmaceuticals on 7 of the 8 factors compared between the two stocks.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Receive News & Ratings for SciClone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply